Welcome to our dedicated page for Guided Thera SEC filings (Ticker: GTHP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA updates, clinical trial costs, and insider trades inside Guided Therapeutics’ lengthy SEC filings can feel like extracting a biopsy result from a mountain of medical charts. Each 10-K details LuViva device revenue streams, while every 8-K may announce pivotal pre-market approvals—yet the information is buried in legal language.
Stock Titan’s AI-powered analysis turns those pages into clear, actionable insights. Need the latest Guided Therapeutics quarterly earnings report 10-Q filing? We summarise margins, R&D burn, and device-unit sales. Curious about Guided Therapeutics insider trading Form 4 transactions? Real-time alerts flag executive stock moves the moment they hit EDGAR, giving you a head start on trend spotting.
Our platform covers every document type investors ask for:
- Form 4 insider dealings—see Guided Therapeutics Form 4 insider transactions real-time
- 10-K annual report—read the Guided Therapeutics annual report 10-K simplified to grasp device market risks
- 10-Q updates—track quarter-over-quarter progress on commercialization
- 8-K event briefs—Guided Therapeutics 8-K material events explained in plain English
- DEF 14A—understand the Guided Therapeutics proxy statement executive compensation package
With AI-generated plain-language summaries, keyword search across footnotes, and section-by-section highlights, understanding Guided Therapeutics SEC documents with AI takes minutes, not days. Professionals use our tools to:
- Monitor executive buying and selling before material announcements
- Compare clinical spend across quarters
- Evaluate royalty obligations hidden in footnotes
Stop sifting through PDFs. Our AI answers the real question: What does Guided Therapeutics’ latest filing mean for your decision today?
Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.
FAQ
What is the current stock price of Guided Thera (GTHP)?
What is the market cap of Guided Thera (GTHP)?
